Journal article
Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial
Kirsten P Perrett, Scott A Halperin, Terry Nolan, Cristina Martinez Pancorbo, Bruce Tapiero, Federico Martinon-Torres, Zbynek Stranak, Miia Virta, Otto G Vanderkooi, Pavel Kosina, Maria Begona Encinas Pardilla, Ignacio Cristobal Garcia, Gian Vincenzo Zuccotti, Lusine Kostanyan, Nadia Meyer, Maria Angeles Ceregido, Brigitte Cheuvart, Sherine O Kuriyakose, Manuel Marcos Fernandez, Miguel Angel Rodriguez Zambrano Show all
Vaccine | ELSEVIER SCI LTD | Published : 2020
Abstract
BACKGROUND: Pertussis immunization during pregnancy is recommended in many countries. Data from large randomized controlled trials are needed to assess the immunogenicity, reactogenicity and safety of this approach. METHODS: This phase IV, observer-blind, randomized, placebo-controlled, multicenter trial assessed immunogenicity, transplacental transfer of maternal pertussis antibodies, reactogenicity and safety of a reduced-antigen-content diphtheria-tetanus-three-component acellular pertussis vaccine (Tdap) during pregnancy. Women received Tdap or placebo at 27-36 weeks' gestation with crossover ≤ 72-hour-postpartum immunization. Immune responses were assessed before the pregnancy dose and ..
View full abstractGrants
Funding Acknowledgements
This work was supported by GlaxoSmithKline Biologicals S.A., which was the funding source, was involved in all stages of the study conduct and analysis and paid for all costs associated with the development and publishing of this manuscript.